Morgan Stanley Maintains Equal-Weight on Sigilon Therapeutics, Raises Price Target to $21
Portfolio Pulse from Benzinga Newsdesk
Morgan Stanley analyst Matthew Harrison maintains an Equal-Weight rating on Sigilon Therapeutics (NASDAQ:SGTX) and raises the price target from $7 to $21.
June 30, 2023 | 1:08 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Morgan Stanley maintains an Equal-Weight rating on Sigilon Therapeutics and raises the price target from $7 to $21.
The news of Morgan Stanley maintaining an Equal-Weight rating on Sigilon Therapeutics and raising the price target from $7 to $21 is directly related to the company and is likely to have a positive impact on its stock price in the short term. Investors may interpret this as a sign of confidence in the company's future performance.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100